citalopram has been researched along with mecamylamine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Isgor, C; Ma, Z; Pearson, E; Tao, R | 1 |
| Andreasen, JT; Redrobe, JP | 1 |
| Lindsley, CW | 1 |
| Gruca, P; Lason-Tyburkiewicz, M; Litwa, E; Papp, M; Willner, P | 1 |
| Demyttenaere, K; Dunbar, G; Eriksson, H; Hosford, D; Möller, HJ; Olausson, B; Szamosi, J; Tummala, R; Wilson, E | 1 |
1 review(s) available for citalopram and mecamylamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for citalopram and mecamylamine
| Article | Year |
|---|---|
(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
Topics: Animals; Antidepressive Agents; Citalopram; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Mecamylamine; Molecular Structure; Multicenter Studies as Topic; Nicotinic Antagonists; Patient Selection; Randomized Controlled Trials as Topic; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 2010 |
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Mecamylamine; Middle Aged; Psychiatric Status Rating Scales; Sertraline; Treatment Outcome; Young Adult | 2015 |
4 other study(ies) available for citalopram and mecamylamine
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Evidence of reuptake inhibition responsible for mecamylamine-evoked increases in extracellular serotonin.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aconitine; Animals; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Mecamylamine; Microdialysis; Nicotinic Antagonists; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Wakefulness | 2006 |
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Mecamylamine; Mice; Morpholines; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Norepinephrine; Reboxetine; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Serotonin | 2009 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumazenil; GABA Modulators; Male; Mecamylamine; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Substance Withdrawal Syndrome; Substance-Related Disorders | 2014 |